ArticleInternational journal of pharmaceutics: X2026
Improved topical delivery of curcumin by mussel adhesive protein functionalized ethosomes for effective psoriasis treatment.
Article in International journal of pharmaceutics: X, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psoriasis is a prevalent inflammatory skin disorder exhibiting a rapidly increasing incidence. Curcumin (Cur) serves as an effective therapeutic agent for psoriasis and is commonly administered through the cutaneous route. Nevertheless, the poor skin permeability and retention of Cur restrict its therapeutic efficacy against psoriasis. In this study, we fabricated mussel adhesion protein (MAP)-modified Cur-loaded ethosomes (Cur-MAP-Es) aimed at enhancing both the permeation and retention of Cur within the skin for improved topical treatment of psoriasis. The average particle size of Cur-MAP-Es was 197.17 nm, and the encapsulation efficiency was 90.84%. The Cur-MAP-Es exhibited a spherical morphology, along with high elasticity, favorable stability, and a prolonged release pattern within 24 h. Additionally, the Cur-MAP-Es exhibited a 3.47-fold higher skin retention compared to the Cur-Es. Intradermal fluorescence distribution analysis indicated that most of the Cur in the Cur-MAP-Es was effectively retained in the epidermis after being delivered into the skin via vesicles. The interaction mechanisms of Cur-MAP-Es with the skin have revealed that Cur-MAP-Es can weaken the skin barrier, thereby facilitating enhanced permeability and drug retention. Furthermore, Cur-MAP-Es could significantly alleviate the inflammation in the mouse model of psoriasis. These results suggest that Cur-MAP-Es may serve as an effective strategy to enhance the topical delivery efficiency of Cur, thereby showing considerable potential in the management of psoriasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.